

# 1 Integrating metabolomics and proteomics to identify novel drug targets for 2 heart failure and atrial fibrillation

3

4 Marion van Vugt<sup>1,2,3</sup>, Chris Finan<sup>1,2,4,5</sup>, Sandesh Chopade<sup>2,4</sup>, Rui Providencia<sup>5</sup>, Connie R.  
5 Bezzina<sup>6</sup>, Folkert W. Asselbergs<sup>3,7,8</sup>, Jessica van Setten<sup>\*1</sup>, A. Floriaan Schmidt<sup>\*1,2,3,4</sup>

6 1. Division Heart & Lungs, Department of Cardiology, University Medical Center  
7 Utrecht, Utrecht University, Utrecht, The Netherlands

8 2. Institute of Cardiovascular Science, Faculty of Population Health, University College  
9 London, London, United Kingdom

10 3. Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam  
11 University Medical Centre, University of Amsterdam, Amsterdam, Netherlands

12 4. UCL British Heart Foundation Research Accelerator, London, United Kingdom

13 5. Health Data Research UK and Institute of Health Informatics, University College  
14 London, London, United Kingdom

15 6. Amsterdam University Medical Centers, Department of Experimental Cardiology,  
16 University of Amsterdam, Amsterdam, The Netherlands

17 7. Institute of Health Informatics, University College London, London, United Kingdom

18 8. The National Institute for Health Research University College London Hospitals  
19 Biomedical Research Centre, University College London, London, United Kingdom

20

21 \*Authors contributed equally

22 Running title: Multi-omics in cardiac diseases

23 Word count text: 3,340

24 Word count abstract: 264

25 Number of references: 68

26 Number of tables and figures: 9

27 Number of (web) appendices: 3

1

2 Corresponding author:

3 Marion van Vugt

4 [rmgpmva@ucl.ac.uk](mailto:rmgpmva@ucl.ac.uk)

1 **Abstract**

2

3 **Background.** Altered metabolism plays a role in the pathophysiology of cardiac diseases,  
4 such as atrial fibrillation (AF) and heart failure (HF). We aimed to identify novel plasma  
5 metabolites and proteins associating with cardiac disease.

6 **Methods.** Mendelian randomisation (MR) was used to assess the association of 174  
7 metabolites measured in up to 86,507 participants with AF, HF, dilated cardiomyopathy  
8 (DCM), and non-ischemic cardiomyopathy (NICM). Subsequently, we sourced data on 1,567  
9 plasma proteins and performed *cis* MR to identify proteins affecting the identified metabolites  
10 as well as the cardiac diseases. Proteins were prioritised on cardiac expression and  
11 druggability, and mapped to biological pathways.

12 **Results.** We identified 35 metabolites associating with cardiac disease. AF was affected by  
13 seventeen metabolites, HF by nineteen, DCM by four, and NICM by taurine. HF was  
14 particularly enriched for phosphatidylcholines ( $p=0.029$ ) and DCM for acylcarnitines  
15 ( $p=0.001$ ). Metabolite involvement with AF was more uniform, spanning for example  
16 phosphatidylcholines, amino acids, and acylcarnitines. We identified 38 druggable proteins  
17 expressed in cardiac tissue, with a directionally concordant effect on metabolites and cardiac  
18 disease. We recapitulated known associations, for example between the drug target of  
19 digoxin (AT1B2), taurine and NICM risk. Additionally, we identified numerous novel findings,  
20 such as higher RET values associating with phosphatidylcholines and decreasing AF and  
21 HF, and RET is targeted by drugs such as regorafenib which has known cardiotoxic side-  
22 effects. Pathway analysis implicated involvement of GDF15 signalling through RET, and  
23 ghrelin regulation of energy homeostasis in cardiac pathogenesis.

24 **Conclusion.** This study identified 35 plasma metabolites involved with cardiac diseases and  
25 linked these to 38 druggable proteins, providing actionable leads for drug development.

26

27 **Keywords:** heart failure, atrial fibrillation, cardiomyopathy, metabolomics, drug  
28 development, Mendelian randomisation, proteomics

## 1 Introduction

2 Atrial fibrillation (AF) and heart failure (HF) are common types of cardiac disease, resulting in  
3 substantial mortality and morbidity, and placing a major burden on healthcare and society<sup>1,2</sup>.  
4 Despite advances in management and understanding of disease pathophysiology, AF and  
5 HF prevalence remain high<sup>1,2</sup>. HF is a particularly heterogeneous disease potentially caused  
6 by cardiomyopathies, such as dilated cardiomyopathy (DCM) and non-ischemic  
7 cardiomyopathy (NICM).

8  
9 Aside from N-terminal prohormone of brain natriuretic peptide (NT-proBNP) used in HF,  
10 troponin in ischemic cardiac disease, and D-dimers in pulmonary embolism, there are no  
11 plasma measurements to inform management of cardiac disease. Analyses of diseased  
12 hearts and cardiomyocytes have shown clear changes in cardiac metabolism, where  
13 diseased cardiomyocytes switch to ketone oxidation and glycolysis<sup>3-5</sup>. Small sample sized  
14 and predominantly cross-sectional studies of AF and HF patients have found elevated  
15 plasma values of acylcarnitines (ACs), which are markers of impaired fatty acid oxidation<sup>6-12</sup>.

16  
17 Metabolic changes characterising cardiac diseases can inform drug development, which is  
18 especially important for HF and AF, where currently available drugs do not necessarily  
19 address underlying aetiology. For example, no novel AF drugs have been approved since  
20 the 2011 introduction of the anticoagulants rivaroxaban, apixaban, and edoxaban, which are  
21 indicated for stroke prevention in AF patient without addressing the underlying cause of AF.

22  
23 Both metabolites and proteins, the main targets of most drugs<sup>13</sup>, are increasingly analysed  
24 by high-throughput assays measuring the plasma values of hundreds of analytes<sup>14-16</sup>.

25 Genome-wide association studies (GWAS) have now identified genetic determinants of  
26 protein and metabolite values, which allow for integrative analyses identifying potential  
27 associations between the protein values, metabolite values, and cardiac disease in humans.  
28 Specifically, through two-sample Mendelian randomisation (MR), one can anticipate the

1 effect an exposure (e.g. a metabolite) will have on the onset of disease by sourcing genetic  
2 variants strongly associated with the exposure and determining whether these variants show  
3 a dose-response association with disease<sup>17,18</sup>. This approach has been extensively validated  
4 for cardiovascular disease<sup>19–22</sup>, including a recent study on plasma proteins affecting cardiac  
5 function and structure as well as cardiac disease<sup>23</sup>.

6  
7 In the current study, we sourced data on 174 metabolites measured in up to 86,507  
8 participants and performed genome-wide MR to identify metabolites associated with AF, HF,  
9 DCM, and NICM. Subsequently, we leveraged data on 1,567 proteins measured in up to  
10 35,559 participants and used *cis* MR to identify proteins affecting both the identified  
11 metabolites and the considered cardiac outcomes. We triangulated and prioritised proteins  
12 with concordant effects on metabolite values and cardiac outcomes. Through the integration  
13 of these omics data we identified 38 drugged and druggable proteins expressed in cardiac  
14 tissue, which affected 35 metabolites and cardiac disease.

## 15 16 **Methods**

### 17 18 *Data sources*

19 Genetic associations with 174 metabolites measured in up to 86,507 participants  
20 were available from Lotta *et al.*<sup>24</sup> (**Supplementary Note**). Plasma protein data were  
21 available from eight GWAS: deCODE (SomaLogic assay, n=35,559)<sup>25</sup>, SCALLOP (OLINK  
22 assay, n=30,931)<sup>26</sup>, Ahola-Olli *et al.* (BioRad assay, n=8,293)<sup>27</sup>, Framingham (Luminex  
23 assay, n=6,861)<sup>28</sup>, AGES-Reykjavik (SomaLogic assay, n=5,368)<sup>29</sup>, INTERVAL (SomaLogic  
24 assay, n=3,301)<sup>30</sup>, Gilly *et al.* (Olink assay, n=1,328)<sup>31</sup>, and Yang *et al.* (SomaLogic assay,  
25 n=636)<sup>32</sup>. Genetic associations with AF were sourced from Nielsen *et al.* (60,620 cases)<sup>33</sup>,  
26 with HF from Shah *et al.* (47,309 cases)<sup>34</sup>, with DCM from Garnier *et al.* (2,719 cases)<sup>35</sup>, and  
27 with NICM from Aragam *et al.* (2,038 cases)<sup>36</sup>.

28

1 *Mendelian randomisation analyses*

2 Genome-wide MR, considering genetic variants from across the genome, was used to  
3 establish associations between metabolite values and cardiac outcomes (step 1 in **Figure**  
4 **1A, Appendix Table S1-2**). Subsequently *cis* MR, sourcing genetic variants from a 200  
5 kilobase pair window around the protein encoding gene<sup>17</sup>, was used to identify plasma  
6 protein effects on metabolite values and cardiac outcomes (step 2-3 in **Figure 1A**).  
7 Irrespective of the type of MR analysis, instruments were selected based on an exposure F-  
8 statistic of at least 24 and a minor allele frequency of at least 0.01. Additionally, variants  
9 were clumped to a linkage disequilibrium r-squared of 0.3, based on a random sample of  
10 5,000 unrelated UK biobank participants of European ancestry.

11  
12 Analyses were conducted using the generalised least squares implementation of the  
13 inverse-variance weighted (IVW) estimator, as well as with an Egger correction protecting  
14 against horizontal pleiotropy<sup>37</sup>. Influence of horizontal pleiotropy was minimised by excluding  
15 variants with a leverage statistic larger than three times the mean, and by excluding variants  
16 with an outlier (i.e. chi-square) statistic larger than 10.83<sup>38</sup>. To ensure we had sufficient data  
17 to accurately model the exposure effects, we discarded analyses with fewer than 6 variants.  
18 Additionally, a model selection strategy was used to select the most appropriate estimator  
19 (IVW or MR-Egger)<sup>38,39</sup>, where the MR-Egger is unbiased in the presence of directional  
20 horizontal pleiotropy. The model selection framework, originally developed by Rücker *et al.*<sup>40</sup>,  
21 uses the difference in heterogeneity between the IVW Q-statistic and the Egger Q-statistic to  
22 decide which method provides the best model to describe the available data. Furthermore,  
23 due to the two-sample nature of our analyses any potential weak-instrument bias would act  
24 toward a null effect, reducing power, rather than increasing type 1 errors<sup>23</sup>.

25

26 *Effect estimates, multiple testing, and nomenclature*

27 MR results are presented as mean difference (MD) for continuous outcomes, or odds ratios  
28 (ORs) for binary outcomes, accompanied by 95% confidence intervals (CIs) and p-values.

1 Metabolite effects on disease were filtered for a multiplicity corrected p-value threshold of  
2  $7 \times 10^{-5}$  based on the 174 available metabolites and four outcomes, which is conservative,  
3 considering many metabolites are correlated. Similarly, protein MR effect estimates were  
4 evaluated against a multiplicity corrected p-value of  $9 \times 10^{-7}$  for the metabolites and  $2 \times 10^{-5}$  for  
5 the cardiac outcomes, based on the number of tested proteins (1,567 in the metabolite MR  
6 and 686 in the cardiac MR) and outcomes (36 in the metabolite MR and four in the cardiac  
7 MR). Proteins are referred to using their Uniprot label and presented in normal font to  
8 differentiate from gene names in italic font.

9

#### 10 *Prioritisation and annotation of proteins*

11 Proteins were prioritised based on the association with a plasma metabolite and a  
12 directionally concordant effect on cardiac outcome. For example, if an increase in a  
13 metabolite value decreased the risk of AF, a protein that increased the value of this  
14 metabolite should decrease AF risk to be deemed concordant. In this way, robust triangles of  
15 associations between the metabolites, proteins, and cardiac outcomes are created (**Figure**  
16 **1B**). Given that this triangulation considers evidence from three separate MR analyses with  
17 distinct underlying assumptions on horizontal pleiotropy, this approach identifies a robust set  
18 of results, highly supported by the available data. For example, *cis* MR analyses assume the  
19 absence of pre-translational pleiotropy, which may be more robust compared to more distal  
20 assumptions on horizontal pleiotropy employed in genome-wide MR<sup>17</sup>.

21

22 The identified proteins were further annotated and prioritised on the presence of cardiac  
23 mRNA expression sourcing information from the human protein atlas (HPA)<sup>41</sup>. Subsequently,  
24 we identified genes which were overexpressed in cardiac tissue through comparisons  
25 against the average mRNA expression across the other 60 available tissues  
26 (**Supplementary Note**). We obtained information on druggability, indications and side-  
27 effects from ChEMBL v33 and the British National Formulary (BNF) identifying proteins as

1 “druggable” if they are targeted by a developmental drug and “drugged” if they are targeted  
2 by an approved compound. Finally, the Reactome<sup>42</sup> knowledgebase was queried to map all  
3 1,567 proteins to biological pathways. Pathway involvement of the prioritised proteins was  
4 compared against the full set of 1,567 proteins using Wald tests.

5

### 6 *Replicating protein associations with metabolites and cardiac disease*

7 The aforementioned *cis* MR analyses sourced data from eight proteomic GWAS, allowing for  
8 replication of the subset of identified proteins that were available in multiple studies. Of the  
9 82 prioritised proteins (see results), 49 were available in multiple studies. For these 49  
10 proteins the largest sample size GWAS was used for discovery and the remaining studies  
11 used for replication. Replication was sought by identifying associations with the same effect  
12 direction as the discovery association, and a p-value smaller than 0.05 (nominal replication)  
13 and  $0.05/49=0.001$  (conservative replication). Please see the **Supplementary Note** for  
14 additional details.

15

## 16 **Results**

17

### 18 *Metabolite effects on cardiac outcomes*

19 Genome-wide MR identified 35 metabolites associating with one or more cardiac disease  
20 (**Figure 2, Appendix Table S2-3**). Acylcarnitines (ACs) were enriched for DCM ( $p=0.001$ ;  
21 **Appendix Table S4**), with higher values of hexadecanoylcarnitine (OR 1.51, 95%CI 1.28;  
22 1.79), octadecanoylcarnitine (OR 1.47, 95%CI 1.25; 1.73), and octadecadienoylcarnitine  
23 (OR 1.38, 95%CI 1.22; 1.55) increasing DCM risk, while higher values of butyrylcarnitine  
24 decreased DCM risk (OR 0.87, 95%CI 0.82; 0.93). Phosphatidylcholines (PCs) were  
25 enriched for HF ( $p=0.029$ ; **Appendix Table S4**) and all thirteen PCs associated with HF  
26 elicited a risk increasing effect. We observed more uniform effects for AF, which was  
27 affected by seventeen plasma metabolites. Finally, we observed that higher values of  
28 plasma taurine decreased NICM risk (OR 0.48, 95%CI 0.38; 0.60; **Figure 2**).



1

2 *Protein effects on metabolite values and cardiac outcomes*

3 We evaluated 1,567 unique plasma proteins for associations with the 35 metabolites  
4 implicated in cardiac disease onset. This resulted in 686 proteins associated with one or  
5 more metabolite (step 2 in **Figure 1A, Appendix Figure S1**). Prioritising proteins on an  
6 association with cardiac outcomes identified 241 proteins (step 3 in **Figure 1A, Appendix**  
7 **Figure S2**), which were pruned down to 87 proteins by identifying the proteins with a  
8 directionally concordant effect on metabolites and cardiac outcomes (**Table 1-4, Appendix**  
9 **Table S5**). This triangulated subset of 87 proteins included 82 proteins that were expressed  
10 in cardiac tissue. Only CYTD, FETUB, PCSK9, PZP, and SPA11 were not expressed in  
11 cardiac tissue and six of the 82 prioritised proteins (ANX11, DNJA4, NAR3, PLXA1, RF1ML,  
12 and TIG1) were significantly overexpressed in the heart compared to other tissues (**Figure**  
13 **3, Appendix Table S6**).

14

15 ChEMBL and BNF were consulted to identify seventeen proteins that were druggable (i.e.,  
16 targeted by a developmental compound) and 21 that were drugged (i.e., targeted by an  
17 approved compound; **Figure 4, Appendix Table S7-8**). Eleven of the 21 drugged proteins  
18 were targeted by drugs with a cardiac indication, side-effect, or both. For example, higher  
19 values of AT1B2 (targeted by HF drug digoxin) increased NICM risk and decreased plasma  
20 taurine values. Furthermore, higher values of DPEP1 (associated with acetylcarnitine  
21 values) and KPCA (associated with tetradecanoylcarnitine and PC ae C38:4 values)  
22 decreased AF risk, while higher values of FA10 (associated with PC ae C42:2 and PC ae  
23 C38:4 values) increased AF risk (**Figure 4**). DPEP1 is inhibited by cilastatin, which is  
24 indicated for endocarditis and is implicated with tachycardia, KPCA is inhibited by  
25 midostaurin, which is known to elicit QT-interval prolongation, and FA10 is inhibited by drugs  
26 like apixaban, edoxaban, and rivaroxaban, which are commonly used to prevent stroke in  
27 AF. The remaining ten drugged proteins were targeted by compounds indicated for

1 treatment of cancers (CAN2, EPHB1, ERAP1, GSTM3, NQO1, and PVRL4), mitochondrial  
2 and muscular disease (NQO1), and metabolic syndrome (CEL; **Appendix Table S8-9**).

3

4 Irrespective of the indication or reported side-effect, drugged or druggable proteins  
5 associating with HF frequently affected phosphatidylcholines values. Higher values of ADH4  
6 (targeted by nitrefazole), EDAR, EPHB1 (targeted by cancer drug vandetanib), ERAP1  
7 (targeted by cancer drug tosedostat), and FCG2A decreased HF risk, while higher values of  
8 APOC3, CAN2 (targeted by amyloidosis drugs bortezomib and carfilzomib), and GRAB  
9 increased HF risk (**Figure 4, Appendix Table S7**). DCM was affected by six drugged or  
10 druggable proteins, all affecting one or more acylcarnitines. Higher values of SAT2 (targeted  
11 by trientine, which is in phase 2 clinical development for hypertrophic cardiomyopathy) and  
12 NUDT9 decreased DCM risk, while FCG3A (the target of imgatuzumab) and CACP (targeted  
13 by levocarnitine, which is being tested for AF and HF) increased DCM risk. Higher values of  
14 CEL (targeted by obesity medicine orlistat), ENTP5 (targeted by the psoriasis drug  
15 anthralin), GMPR2, GFRA1 (targeted by liatermin, a phase 1 compound for Parkinson's  
16 disease), IBP3, and TEC (targeted by Pf-06651600, which is in clinical testing for arthritis,  
17 kidney and Crohn's disease) decreased AF risk, while ENASE (targeted by AF drug  
18 edoxaban), GSTM3 (targeted by carmustine), IGFR1, TDGF1 (targeted by the antibody biib-  
19 015 used to treat cancer), and TRYB1 (targeted by arginine, which is being tested for HF)  
20 increased AF risk, affecting metabolites of various classes (**Figure 4, Appendix Table S7-  
21 8**). Four drugs target more than one prioritised protein: Cep-2563 targets KPCA and RET,  
22 edoxaban targets ENASE and FA10, nitrefazole targets ADH1B and ADH4, and vandetanib  
23 targets EPHB1 and RET (**Appendix Table S8**).

24

25 Ten pleiotropic proteins affected multiple cardiac outcomes (**Figure 5**). For example, higher  
26 values of ACES (inhibited by pyridostigmine bromide, which is in phase 2 testing for HF),  
27 DNJA4, and PLXB2 increased AF and HF risk, whereas higher values of IL6RA (targeted by  
28 tocilizumab), NEC1, and RET (targeted by regorafenib, which has cardiac side-effects)

1 decreased AF and HF risk. Higher values of APOC3 and FCG3A increased HF and DCM  
2 risk. ENOB increased the risk of HF (OR 1.05, 95%CI 1.03; 1.08), DCM (OR 1.39, 95%CI  
3 1.28; 1.50), and NICM (OR 1.24, 95%CI 1.13; 1.35; **Figure 5, Appendix Table S7**).

4

#### 5 *Identifying enriched biological pathways*

6 We used the Reactome knowledgebase<sup>42</sup> to identify enriched pathways among the  
7 prioritised proteins which identified three enriched pathways involving seven of the prioritised  
8 proteins. Specifically, GFRA1, KPCA, and RET were involved in the “RET signalling”  
9 pathway, TPSN and ERAP1 in “antigen presentation: folding, assembly and peptide loading  
10 of class I MHC”, and ACES and NEC1 in the “synthesis, secretion, and deacylation of  
11 ghrelin” pathway (**Appendix Table S10**).

12

#### 13 *Replicating protein associations with cardiac disease*

14 Replication data from independent plasma protein data were available for 49 out of 82  
15 prioritised proteins. Applying a nominal replication p-value of 0.05, we were able to replicate  
16 the cardiac association of 38 proteins (77.6%; **Appendix Table S11**). The effects of 24  
17 proteins were replicated more than once, with the IL6RA effects on AF and HF replicated in  
18 up to five studies. Applying a multiple testing adjusted p-value cut-off, resulted in 30  
19 replicated proteins (61.2%), also including IL6RA. Please see the **Supplementary Note** for  
20 replication of the protein association with plasma metabolite values.

21

## 22 **Discussion**

23 In the current study we integrated genetic associations with 174 metabolites and 1,567  
24 proteins to identify determinants of cardiac disease relevant for de novo drug development  
25 and drug repurposing. Results were prioritised on concordant effect direction and cardiac  
26 tissue expression, identifying 82 triangulated proteins and 35 metabolites associating with  
27 AF, HF, DCM, and NICM. Plasma acylcarnitine (AC) values were strongly related with DCM,  
28 while phosphatidylcholine (PC) values were important determinants of HF. Metabolites

1 affecting AF spanned six metabolite classes, potentially reflecting the heterogeneous  
2 aetiology of AF. We identified ten pleiotropic proteins affecting multiple cardiac traits: ACES,  
3 APOC3, DNJA4, ENOB, FCG3A, IL6RA, NEC1, PLA2R, PLXB2, and RET. The 38 drugged  
4 and druggable proteins included eleven proteins with a known cardiac indication, side-effect,  
5 or both: ACES (donepezil), AT1B2 (digoxin), CACP (levocarnitine), DPEP1 (cilastatin),  
6 ENASE (edoxaban), FA10 (apixaban), IL6RA (tocilizumab), KPCA (midostaurin), RET  
7 (regorafenib), SAT2 (trientine), and TRYB1 (arginine). Pathway enrichment identified  
8 proteins involved in GDF15-dependent RET signalling, ghrelin homeostasis, and MHC I  
9 antigen presentation.

10

11 ACs were strongly associated with DCM onset, with prioritised proteins affecting DCM also  
12 associating with long-chain (hexadecanoylcarnitine, octadecanoylcarnitine,  
13 octadecadienoylcarnitine) and short-chain (butyrylcarnitine) AC values (**Table 3, Appendix**  
14 **Table S7**). Higher AC values additionally increased AF (propionylcarnitine and  
15 tetradecanoylcarnitine), and HF risk (acetylcarnitine). AC values are indicators of fatty acid  
16 oxidation, the main energy substrate of the healthy heart<sup>4</sup>, with particularly long-chain ACs  
17 the results of fatty acid metabolism<sup>43</sup>, while short-chain ACs are more generally synthesised  
18 during glucose, AA and fatty acid metabolism<sup>43</sup>. Fourteen drugged and druggable proteins  
19 associated with AC plasma values (**Appendix Table S7**). We showed that ACES affects the  
20 plasma values of several ACs and was associated with a risk increasing effect on AF and  
21 HF. ACES is targeted by several drugs with cardiac side-effects and inhibited by  
22 pyridostigmine bromide, which is being tested for HF (**Appendix Table S8**), increases heart  
23 rate variability, and reduces ventricular arrhythmias in chronic HF patients<sup>44</sup>, supporting the  
24 identified associations. NEC1 affects several PCs, AF, and HF, is a druggable protein that  
25 processes hormones such as insulin and its encoding gene *PCSK1* associated with HF risk  
26 factors such as obesity<sup>45</sup> and abnormal glucose homeostasis<sup>46</sup>. NEC1 and ACES are  
27 involved in the enriched ghrelin pathway (**Appendix Table S10**), which regulates energy

1 homeostasis and plays a role in myocardial function<sup>47-50</sup>. Ghrelin was therefore proposed as  
2 a novel target for HF management<sup>51</sup>.

3

4 We identified thirteen PCs that increased HF risk, of which five also increased AF risk.  
5 These results suggest that PCs play an important role in cardiac function, which is supported  
6 by the findings that PCs are implicated in aberrant calcium handling<sup>52,53</sup>. We identified  
7 sixteen drugged and druggable proteins affecting PC values as well as AF or HF, or both  
8 (**Appendix Table S7**). Higher ERAP1 values (targeted by tosedostat) were shown to  
9 decrease plasma PC values and HF risk, is targeted by cancer drug tosedostat, and plays a  
10 role in blood pressure regulation<sup>54</sup>. Together with the not yet druggable protein TPSN,  
11 ERAP1 is involved in the enriched MHC I antigen presentation pathway which is linked to  
12 CD8+ T-cell mediated cardiac remodelling leading to HF<sup>55</sup>. We additionally found that higher  
13 KPCA values decreased AC and PC values and protected against AF. KPCA is targeted by  
14 HF drug midostaurin, and is involved in the significantly enriched RET signalling pathway,  
15 together with GFRA1 and RET (**Appendix Table S10**). The RET receptor is activated by  
16 GFRA1 and is needed for GDF15 signalling<sup>56</sup>, where GDF15 concentrations are predictive of  
17 HF outcome<sup>57,58</sup>. GDF15 has also been shown to associate with stroke, bleeding, and  
18 mortality in AF patients<sup>59</sup>. Furthermore, our observation that increased RET values are  
19 protective against AF and HF may indicate that the adverse effects of RET-inhibiting cancer  
20 drug regorafenib, such as hypertension and myocardial infarction, are on-target (**Table 1-2**,  
21 **Figure 4-5**).

22

23 We wish to discuss the following potential limitations. Firstly, our analyses focussed on  
24 plasma metabolites and proteins, which may not necessarily reflect in cardiac tissue  
25 values<sup>60</sup>. Evidence suggests that plasma values may serve as biomarkers of intracellular  
26 energy metabolism<sup>8,61</sup> and correlate with metabolite values in cardiac tissues, for example  
27 cardiac profiles of medium- and long-chain ACs have been found to reflect plasma  
28 concentrations<sup>43</sup>. This is further supported by our observation that 82 of the 87 triangulated

1 plasma proteins were expressed in cardiac tissue. It is important to note that proteins without  
2 cardiac expression can affect cardiac function, thereby contributing to disease development.  
3 PCSK9, for example, was one of five proteins not expressed in cardiac tissue (**Figure 3**) but  
4 is anticipated to decrease HF risk through prevention of progressive CHD<sup>20,62–64</sup>. Additionally,  
5 animal studies suggest that PCSK9 inhibition may induce an LDL receptor-mediated  
6 improvement in cardiac lipid metabolism<sup>65</sup>, providing illustrations of plasma protein  
7 involvement with cardiac metabolism. A second potential limitation is our reliance on high  
8 throughput assays, which differ in terms of accuracy and coverage<sup>66</sup> and measure relative  
9 protein or metabolite values rather than concentrations. This implies that the reported effect  
10 estimates and their magnitudes need not directly translate to anticipated clinical effects,  
11 hence small effects may nevertheless mark potentially clinically impactful targets. Rather we  
12 suggest a focus on effect direction, providing information on the type of perturbation  
13 (activating versus inhibiting), might be more informative. Third, while MR studies are  
14 susceptible to bias through horizontal pleiotropy, we mitigate this source of bias by removing  
15 potentially pleiotropic variants, employing a model selection framework, and triangulating  
16 results across analysis with distinct pleiotropy assumptions. Specifically, our triangulation  
17 approach minimized the potential for horizontal pleiotropy, by looking for agreement across  
18 three distinct MR analyses which also made distinct assumptions on horizontal pleiotropy.  
19 The robustness of this approach is highlighted by the rediscovery of multiple cardiac drug  
20 targets such as edoxaban, apixaban, and rivaroxaban for AF and digoxin for HF. The  
21 triangulation of AT1B2 with taurine and NICM is particularly illustrative, because taurine  
22 supplementation may be used to replace or reduce the dosage of digoxin prescription in  
23 HF<sup>67</sup>. Finally, we emphasise that we were able to replicate associations for up to 77.6% of  
24 the proteins available in multiple studies.

25

26 In conclusion, we identify 35 metabolites and 38 drugged or druggable proteins associating  
27 with AF, HF, DCM, and NICM. We were able to relate these findings to biological pathways

- 1 relating to energy homeostasis through ghrelin and GDF15 signalling. Our findings provide
- 2 insight into pathogenesis of cardiac disease and leads for cardiac drug development.

1 **Data availability**

2 All scripts and aggregated data are available online at <URL available upon publication>.

3

4 **Non-standard abbreviations and acronyms**

5 AA = amino acid

6 AC = acylcarnitine

7 AF = atrial fibrillation

8 BNF = British National Formulary

9 CI = confidence interval

10 DCM = dilated cardiomyopathy

11 EGFR = epidermal growth factor receptor

12 GWAS = genome-wide association studies

13 HF = heart failure

14 HPA = human protein atlas

15 IQR = interquartile range

16 IVW = inverse-variance weighted

17 LPC = lysophosphatidylcholine

18 MD = mean difference

19 MR = mendelian randomisation

20 NICM = non-ischemic cardiomyopathy

21 nTPM = normalised transcripts per million

22 NT-proBNP = N-terminal prohormone of brain natriuretic peptide

23 OR = odds ratio

24 PC = phosphatidylcholine

25 SM = sphingomyelin

26



## 1   **References**

- 2   1. Elliott, A. D., Middeldorp, M. E., Van Gelder, I. C., Albert, C. M. & Sanders, P.  
3       Epidemiology and modifiable risk factors for atrial fibrillation. *Nat. Rev. Cardiol.* 1–14  
4       (2023).
- 5   2. Ziaeeian, B. & Fonarow, G. C. Epidemiology and aetiology of heart failure. *Nat. Rev.*  
6       *Cardiol.* **13**, 368–378 (2016).
- 7   3. Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R. & Abel, E. D. Cardiac energy  
8       metabolism in heart failure. *Circ. Res.* **128**, 1487–1513 (2021).
- 9   4. Dambrova, M. *et al.* Acylcarnitines: nomenclature, biomarkers, therapeutic potential,  
10       drug targets, and clinical trials. *Pharmacol. Rev.* **74**, 506–551 (2022).
- 11  5. Wiersma, M. *et al.* Mitochondrial dysfunction underlies cardiomyocyte remodeling in  
12       experimental and clinical atrial fibrillation. *Cells* **8**, 1202 (2019).
- 13  6. Ueland, T. *et al.* Disturbed carnitine regulation in chronic heart failure—increased plasma  
14       levels of palmitoyl-carnitine are associated with poor prognosis. *Int. J. Cardiol.* **167**,  
15       1892–1899 (2013).
- 16  7. Ahmad, T. *et al.* Prognostic implications of long-chain acylcarnitines in heart failure and  
17       reversibility with mechanical circulatory support. *J. Am. Coll. Cardiol.* **67**, 291–299  
18       (2016).
- 19  8. Hunter, W. G. *et al.* Metabolomic profiling identifies novel circulating biomarkers of  
20       mitochondrial dysfunction differentially elevated in heart failure with preserved versus  
21       reduced ejection fraction: evidence for shared metabolic impairments in clinical heart  
22       failure. *J. Am. Heart Assoc.* **5**, e003190 (2016).
- 23  9. Ruiz, M. *et al.* Circulating acylcarnitine profile in human heart failure: a surrogate of fatty  
24       acid metabolic dysregulation in mitochondria and beyond. *Am. J. Physiol.-Heart Circ.*  
25       *Physiol.* **313**, H768–H781 (2017).
- 26  10. Zordoky, B. N. *et al.* Metabolomic fingerprint of heart failure with preserved ejection  
27       fraction. *PloS One* **10**, e0124844 (2015).

- 1 11. Ruiz-Canela, M. *et al.* Plasma acylcarnitines and risk of incident heart failure and atrial  
2 fibrillation: the Prevención con dieta mediterránea study. *Rev. Esp. Cardiol. Engl. Ed.* **75**,  
3 649–658 (2022).
- 4 12. Smith, E., Fernandez, C., Melander, O. & Ottosson, F. Altered acylcarnitine metabolism  
5 is associated with an increased risk of atrial fibrillation. *J. Am. Heart Assoc.* **9**, e016737  
6 (2020).
- 7 13. Finan, C. *et al.* The druggable genome and support for target identification and validation  
8 in drug development. *Sci. Transl. Med.* **9**, eaag1166 (2017).
- 9 14. Soininen, P. *et al.* High-throughput serum NMR metabonomics for cost-effective holistic  
10 studies on systemic metabolism. *Analyst* **134**, 1781–1785 (2009).
- 11 15. Würtz, P. *et al.* Quantitative serum nuclear magnetic resonance metabolomics in large-  
12 scale epidemiology: a primer on-omic technologies. *Am. J. Epidemiol.* **186**, 1084–1096  
13 (2017).
- 14 16. Gold, L. *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery.  
15 *Nat. Preced.* 1–1 (2010).
- 16 17. Schmidt, A. F. *et al.* Genetic drug target validation using Mendelian randomisation. *Nat.*  
17 *Commun.* **11**, 3255 (2020).
- 18 18. Schmidt, A. F., Hingorani, A. D. & Finan, C. Human genomics and drug development.  
19 *Cold Spring Harb. Perspect. Med.* **12**, (2022).
- 20 19. Consortium, I.-6 R. M. R. A. (IL6R M. & others. The interleukin-6 receptor as a target for  
21 prevention of coronary heart disease: a mendelian randomisation analysis. *The Lancet*  
22 **379**, 1214–1224 (2012).
- 23 20. Schmidt, A. F. *et al.* Cholesteryl ester transfer protein (CETP) as a drug target for  
24 cardiovascular disease. *Nat. Commun.* **12**, 5640 (2021).
- 25 21. Zheng, J. *et al.* Phenome-wide Mendelian randomization mapping the influence of the  
26 plasma proteome on complex diseases. *Nat. Genet.* **52**, 1122–1131 (2020).

- 1 22. Cupido, A. J. *et al.* Joint genetic inhibition of PCSK9 and CETP and the association with  
2 coronary artery disease: a factorial Mendelian randomization study. *JAMA Cardiol.* **7**,  
3 955–964 (2022).
- 4 23. Schmidt, A. F. *et al.* Druggable proteins influencing cardiac structure and function:  
5 Implications for heart failure therapies and cancer cardiotoxicity. *Sci. Adv.* **9**, eadd4984  
6 (2023).
- 7 24. Lotta, L. A. *et al.* A cross-platform approach identifies genetic regulators of human  
8 metabolism and health. *Nat. Genet.* **53**, 54–64 (2021).
- 9 25. Ferkingstad, E. *et al.* Large-scale integration of the plasma proteome with genetics and  
10 disease. *Nat. Genet.* **53**, 1712–1721 (2021).
- 11 26. Folkersen, L. *et al.* Genomic and drug target evaluation of 90 cardiovascular proteins in  
12 30,931 individuals. *Nat. Metab.* **2**, 1135–1148 (2020).
- 13 27. Ahola-Olli, A. V. *et al.* Genome-wide association study identifies 27 loci influencing  
14 concentrations of circulating cytokines and growth factors. *Am. J. Hum. Genet.* **100**, 40–  
15 50 (2017).
- 16 28. Yao, C. *et al.* Genome-wide mapping of plasma protein QTLs identifies putatively causal  
17 genes and pathways for cardiovascular disease. *Nat. Commun.* **9**, 3268 (2018).
- 18 29. Gudjonsson, A. *et al.* A genome-wide association study of serum proteins reveals shared  
19 loci with common diseases. *Nat. Commun.* **13**, 480 (2022).
- 20 30. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79  
21 (2018).
- 22 31. Gilly, A. *et al.* Whole-genome sequencing analysis of the cardiometabolic proteome. *Nat.*  
23 *Commun.* **11**, 6336 (2020).
- 24 32. Yang, C. *et al.* Genomic atlas of the proteome from brain, CSF and plasma prioritizes  
25 proteins implicated in neurological disorders. *Nat. Neurosci.* **24**, 1302–1312 (2021).
- 26 33. Nielsen, J. B. *et al.* Biobank-driven genomic discovery yields new insight into atrial  
27 fibrillation biology. *Nat. Genet.* **50**, 1234–1239 (2018).

- 1 34. Shah, S. *et al.* Genome-wide association and Mendelian randomisation analysis provide  
2 insights into the pathogenesis of heart failure. *Nat. Commun.* **11**, 1–12 (2020).
- 3 35. Garnier, S. *et al.* Genome-wide association analysis in dilated cardiomyopathy reveals  
4 two new players in systolic heart failure on chromosomes 3p25. 1 and 22q11. 23. *Eur.*  
5 *Heart J.* **42**, 2000–2011 (2021).
- 6 36. Aragam, K. G. *et al.* Phenotypic refinement of heart failure in a national biobank  
7 facilitates genetic discovery. *Circulation* **139**, 489–501 (2019).
- 8 37. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid  
9 instruments: effect estimation and bias detection through Egger regression. *Int. J.*  
10 *Epidemiol.* **44**, 512–525 (2015).
- 11 38. Bowden, J. *et al.* A framework for the investigation of pleiotropy in two-sample summary  
12 data Mendelian randomization. *Stat. Med.* **36**, 1783–1802 (2017).
- 13 39. Bowden, J. *et al.* Improving the visualization, interpretation and analysis of two-sample  
14 summary data Mendelian randomization via the Radial plot and Radial regression. *Int. J.*  
15 *Epidemiol.* **47**, 1264–1278 (2018).
- 16 40. Rücker, G., Schwarzer, G., Carpenter, J. R., Binder, H. & Schumacher, M. Treatment-  
17 effect estimates adjusted for small-study effects via a limit meta-analysis. *Biostatistics*  
18 **12**, 122–142 (2011).
- 19 41. Uhlen, M. *et al.* Towards a knowledge-based human protein atlas. *Nat. Biotechnol.* **28**,  
20 1248–1250 (2010).
- 21 42. Jassal, B. *et al.* The reactome pathway knowledgebase. *Nucleic Acids Res.* **48**, D498–  
22 D503 (2020).
- 23 43. Makrecka-Kuka, M. *et al.* Plasma acylcarnitine concentrations reflect the acylcarnitine  
24 profile in cardiac tissues. *Sci. Rep.* **7**, 17528 (2017).
- 25 44. Behling, A. *et al.* Cholinergic stimulation with pyridostigmine reduces ventricular  
26 arrhythmia and enhances heart rate variability in heart failure. *Am. Heart J.* **146**, 494–  
27 500 (2003).

- 1 45. Benzinou, M. *et al.* Common nonsynonymous variants in PCSK1 confer risk of obesity.  
2 *Nat. Genet.* **40**, 943–945 (2008).
- 3 46. Heni, M. *et al.* Association of obesity risk SNPs in PCSK1 with insulin sensitivity and  
4 proinsulin conversion. (2010).
- 5 47. Nagaya, N. *et al.* Effects of ghrelin administration on left ventricular function, exercise  
6 capacity, and muscle wasting in patients with chronic heart failure. *Circulation* **110**,  
7 3674–3679 (2004).
- 8 48. Beiras-Fernandez, A. *et al.* Altered myocardial expression of ghrelin and its receptor  
9 (GHSR-1a) in patients with severe heart failure. *Peptides* **31**, 2222–2228 (2010).
- 10 49. Ma, T. *et al.* Ghrelin expression and significance in 92 patients with atrial fibrillation.  
11 *Anatol. J. Cardiol.* **18**, 99 (2017).
- 12 50. Yuan, M.-J., Li, W. & Zhong, P. Research progress of ghrelin on cardiovascular disease.  
13 *Biosci. Rep.* **41**, BSR20203387 (2021).
- 14 51. Nagaya, N. & Kangawa, K. Therapeutic potential of ghrelin in the treatment of heart  
15 failure. *Drugs* **66**, 439–448 (2006).
- 16 52. Li, Y. *et al.* Enrichment of endoplasmic reticulum with cholesterol inhibits sarcoplasmic-  
17 endoplasmic reticulum calcium ATPase-2b activity in parallel with increased order of  
18 membrane lipids: implications for depletion of endoplasmic reticulum calcium stores and  
19 apoptosis in cholesterol-loaded macrophages. *J. Biol. Chem.* **279**, 37030–37039 (2004).
- 20 53. Fu, S. *et al.* Aberrant lipid metabolism disrupts calcium homeostasis causing liver  
21 endoplasmic reticulum stress in obesity. *Nature* **473**, 528–531 (2011).
- 22 54. Cifaldi, L., Romania, P., Lorenzi, S., Locatelli, F. & Fruci, D. Role of endoplasmic  
23 reticulum aminopeptidases in health and disease: from infection to cancer. *Int. J. Mol.*  
24 *Sci.* **13**, 8338–8352 (2012).
- 25 55. Komai, K. *et al.* Single-cell analysis revealed the role of CD8+ effector T cells in  
26 preventing cardioprotective macrophage differentiation in the early phase of heart failure.  
27 *Front. Immunol.* **12**, 763647 (2021).

- 1 56. Buchholz, K. *et al.* Expression of the Body-Weight Signaling Players: GDF15, GFRAL  
2 and RET and their clinical relevance in Gastric Cancer. *J. Cancer* **12**, 4698 (2021).
- 3 57. Rochette, L., Zeller, M., Cottin, Y. & Vergely, C. Insights into mechanisms of GDF15 and  
4 receptor GFRAL: therapeutic targets. *Trends Endocrinol. Metab.* **31**, 939–951 (2020).
- 5 58. Xu, J. *et al.* GDF15/MIC-1 functions as a protective and antihypertrophic factor released  
6 from the myocardium in association with SMAD protein activation. *Circ. Res.* **98**, 342–  
7 350 (2006).
- 8 59. Wallentin, L. *et al.* Growth differentiation factor 15, a marker of oxidative stress and  
9 inflammation, for risk assessment in patients with atrial fibrillation: insights from the  
10 Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation  
11 (ARISTOTLE) trial. *Circulation* **130**, 1847–1858 (2014).
- 12 60. Flam, E. *et al.* Integrated landscape of cardiac metabolism in end-stage human  
13 nonischemic dilated cardiomyopathy. *Nat. Cardiovasc. Res.* **1**, 817–829 (2022).
- 14 61. Rinaldo, P., Cowan, T. M. & Matern, D. Acylcarnitine profile analysis. *Genet. Med.* **10**,  
15 151–156 (2008).
- 16 62. Cohen, J. C., Boerwinkle, E., Mosley Jr, T. H. & Hobbs, H. H. Sequence variations in  
17 PCSK9, low LDL, and protection against coronary heart disease. *N. Engl. J. Med.* **354**,  
18 1264–1272 (2006).
- 19 63. Sabatine, M. S. *et al.* Evolocumab and clinical outcomes in patients with cardiovascular  
20 disease. *N. Engl. J. Med.* **376**, 1713–1722 (2017).
- 21 64. Schmidt, A. F. *et al.* PCSK9 monoclonal antibodies for the primary and secondary  
22 prevention of cardiovascular disease. *Cochrane Database Syst. Rev.* (2017).
- 23 65. Da Dalt, L. *et al.* PCSK9 deficiency rewires heart metabolism and drives heart failure  
24 with preserved ejection fraction. *Eur. Heart J.* **42**, 3078–3090 (2021).
- 25 66. Katz, D. H. *et al.* Proteomic profiling platforms head to head: leveraging genetics and  
26 clinical traits to compare aptamer-and antibody-based methods. *Sci. Adv.* **8**, eabm5164  
27 (2022).

- 1 67. Schaffer, S. & Kim, H. W. Effects and mechanisms of taurine as a therapeutic agent.
- 2 *Biomol. Ther.* **26**, 225 (2018).
- 3

## Tables

**Table 1.** Overview and characteristics of prioritised proteins and metabolites associated with AF

<i>Uniprot ID</i>	<i>Protein</i>	<i>Druggability*</i>	<i>Metabolite class(es)*</i>	<i>No. metabolites*</i>	<i>Metabolite effect*</i>	<i>Cardiac effect*</i>	<i>No. drugs*</i>	<i>Cardiac drug effect*</i>
P22303	ACES	Drugged	Acylcarnitines	1	Increasing	1.09 (1.05; 1.13)	23	Yes
P14621	ACYP2	Not yet druggable	Amino acids	1	Increasing	0.84 (0.80; 0.88)	0	
O75882	ATR	Not yet druggable	Acylcarnitines	1	Increasing	0.94 (0.93; 0.96)	0	
O75973	C1QRF	Not yet druggable	Sphingomyelins, Phosphatidylcholines	2	Increasing	1.05 (1.04; 1.07)	0	
P80075	CCL8	Not yet druggable	Lysophosphatidylcholines	1	Increasing	1.02 (1.01; 1.03)	0	
P19835	CEL	Drugged	Biogenic amines	1	Decreasing	0.95 (0.93; 0.97)	1	
Q8WW22	DNJA4	Not yet druggable	Phosphatidylcholines	1	Decreasing	1.34 (1.26; 1.44)	0	
P16444	DPEP1	Drugged	Biogenic amines	1	Decreasing	0.97 (0.96; 0.98)	2	Yes
Q8NFI3	ENASE	Drugged	Lysophosphatidylcholines	1	Decreasing	1.06 (1.03; 1.08)	12	Yes
O75356	ENTP5	Drugged	Acylcarnitines	1	Increasing	0.89 (0.86; 0.93)	1	
P00742	FA10	Drugged	Phosphatidylcholines	2	Increasing	1.11 (1.06; 1.15)	13	Yes
P16930	FAAA	Not yet druggable	Phosphatidylcholines	1	Decreasing	0.90 (0.88; 0.92)	0	
Q6BAA4	FCRLB	Not yet druggable	Amino acids	1	Increasing	1.13 (1.08; 1.18)	0	
O95479	G6PE	Not yet druggable	Phosphatidylcholines	1	Decreasing	0.96 (0.94; 0.98)	0	
P56159	GFRA1	Druggable	Phosphatidylcholines	1	Increasing	0.91 (0.89; 0.94)	1	
O94923	GLCE	Not yet druggable	Sphingomyelins, Phosphatidylcholines	2	Mixed	0.94 (0.93; 0.95)	0	
Q9P2T1	GMPR2	Druggable	Phosphatidylcholines	2	Increasing	0.93 (0.90; 0.96)	0	
Q9UJ9	GNPTG	Not yet druggable	Sphingomyelins	1	Increasing	0.94 (0.92; 0.96)	0	
P21266	GSTM3	Drugged	Sphingomyelins, Biogenic amines	2	Mixed	1.04 (1.02; 1.05)	1	
P17936	IBP3	Druggable	Acylcarnitines	1	Increasing	0.93 (0.91; 0.96)	0	
Q9H665	IGFR1	Druggable	Biogenic amines	1	Decreasing	1.05 (1.03; 1.08)	0	
Q13478	IL18R	Druggable	Acylcarnitines, Lysophosphatidylcholines	2	Increasing	0.95 (0.94; 0.97)	1	
P08887	IL6RA	Drugged	Sphingomyelins	1	Increasing	0.96 (0.96; 0.97)	7	Yes
P20155	ISK2	Not yet druggable	Phosphatidylcholines	1	Increasing	1.10 (1.07; 1.14)	0	
P17252	KPCA	Drugged	Acylcarnitines, Phosphatidylcholines	2	Increasing	0.81 (0.74; 0.89)	5	Yes
O75023	LIRB5	Not yet druggable	Amino acids	1	Increasing	1.02 (1.01; 1.03)	0	
O15232	MATN3	Not yet druggable	Sphingomyelins, Phosphatidylcholines	2	Increasing	0.97 (0.96; 0.98)	0	
P61244	MAX	Druggable	Lysophosphatidylcholines	1	Decreasing	1.09 (1.05; 1.14)	0	
Q29983	MICA	Not yet druggable	Acylcarnitines, Amino acids	2	Increasing	1.02 (1.02; 1.03)	0	
Q13508	NAR3	Not yet druggable	Amino acids, Lysophosphatidylcholines	2	Increasing	1.07 (1.04; 1.11)	0	
P29120	NEC1	Druggable	Phosphatidylcholines, Sphingomyelins	3	Increasing	0.96 (0.94; 0.97)	0	
Q14554	PDIA5	Not yet druggable	Amino acids, Phosphatidylcholines, Biogenic amines	3	Mixed	1.03 (1.02; 1.05)	0	
O15031	PLXB2	Not yet druggable	Amino acids, Phosphatidylcholines	2	Increasing	1.05 (1.04; 1.06)	0	
Q6UW15	REG3G	Not yet druggable	Phosphatidylcholines	1	Increasing	0.97 (0.96; 0.98)	0	
P07949	RET	Drugged	Acylcarnitines, Amino acids	2	Increasing	0.94 (0.93; 0.95)	14	Yes
P13385	TDGF1	Druggable	Sphingomyelins, Phosphatidylcholines	2	Mixed	1.03 (1.02; 1.04)	1	
P42680	TEC	Drugged	Sphingomyelins	1	Increasing	0.87 (0.83; 0.90)	1	
Q92563	TICN2	Not yet druggable	Acylcarnitines, Phosphatidylcholines	2	Increasing	0.91 (0.89; 0.94)	0	
P35625	TIMP3	Not yet druggable	Phosphatidylcholines	1	Decreasing	1.03 (1.02; 1.04)	0	
O15533	TPSN	Not yet druggable	Phosphatidylcholines	4	Increasing	0.96 (0.95; 0.98)	0	
Q15661	TRYB1	Drugged	Acylcarnitines	1	Increasing	1.02 (1.01; 1.03)	1	Yes
P49746	TSP3	Not yet druggable	Phosphatidylcholines	2	Increasing	0.55 (0.44; 0.69)	0	



N.B. *Druggability* – whether the protein is targeted by a developmental (“druggable”) or approved (“drugged”) compound, *Metabolite class(es)* – metabolite class(es) of the metabolites with which the indicated protein is associated, *No. metabolites* – number of metabolites the protein is associated with, *Metabolite effect* – effect of protein on metabolites, defined as increasing if higher values of the protein increase the plasma metabolite values, decreasing if higher values of the protein decrease the metabolite values, and mixed if higher values of the protein increase values of some and decrease values of other metabolites, *Cardiac effect* – odds ratio (95% confidence interval) of the association between the protein and atrial fibrillation (AF), *No. drugs* – number of drugs that target the indicated protein, *Cardiac drug effect* – whether at least one drug has a cardiac indication or side-effect as indicated by BNF or ChEMBL.

**Table 2.** Overview and characteristics of prioritised proteins and metabolites associated with HF

Uniprot ID	Protein	Druggability*	Metabolite class(es)*	No. metabolites*	Metabolite effect*	Cardiac effect*	No. drugs*	Cardiac drug effect*
P22303	ACES	Drugged	Acylcarnitines	1	Increasing	1.06 (1.04; 1.08)	23	Yes
P00326	ADH1B	Druggable	Acylcarnitines	1	Increasing	1.14 (1.08; 1.20)	2	
P08319	ADH4	Druggable	Phosphatidylcholines	5	Increasing	0.70 (0.61; 0.80)	1	
P50995	ANX11	Not yet druggable	Amino acids	1	Increasing	0.86 (0.82; 0.90)	0	
P02656	APOC3	Druggable	Phosphatidylcholines, Acylcarnitines	5	Increasing	1.29 (1.18; 1.41)	0	
P17655	CAN2	Drugged	Amino acids, Phosphatidylcholines	2	Increasing	1.21 (1.13; 1.29)	2	
Q9UBX1	CATF	Drugged	Amino acids	1	Increasing	0.92 (0.90; 0.94)	2	
Q96EE4	CC126	Not yet druggable	Amino acids	1	Increasing	1.07 (1.04; 1.09)	0	
Q5QGZ9	CL12A	Not yet druggable	Amino acids	1	Increasing	0.99 (0.98; 0.99)	0	
Q8WW22	DNJA4	Not yet druggable	Amino acids	1	Increasing	1.23 (1.14; 1.33)	0	
Q9UNE0	EDAR	Druggable	Phosphatidylcholines	6	Increasing	0.92 (0.88; 0.95)	0	
P13929	ENOB	Not yet druggable	Amino acids, Phosphatidylcholines	2	Increasing	1.05 (1.03; 1.08)	0	
P54762	EPHB1	Drugged	Phosphatidylcholines, Amino acids	2	Mixed	0.95 (0.93; 0.97)	1	
Q9NZ08	ERAP1	Druggable	Phosphatidylcholines	2	Increasing	0.97 (0.96; 0.98)	1	
P12318	FCG2A	Druggable	Phosphatidylcholines	1	Increasing	0.99 (0.98; 0.99)	0	
P08637	FCG3A	Druggable	Phosphatidylcholines	1	Increasing	1.01 (1.01; 1.02)	1	
P10144	GRAB	Drugged	Phosphatidylcholines	2	Increasing	1.21 (1.11; 1.32)	0	
Q96D42	HAVR1	Not yet druggable	Amino acids	1	Increasing	1.06 (1.04; 1.08)	0	
P08887	IL6RA	Drugged	Sphingomyelins	1	Increasing	0.98 (0.97; 0.99)	7	Yes
Q07866	KLC1	Not yet druggable	Amino acids, Sphingomyelins	2	Increasing	1.28 (1.20; 1.38)	0	
Q29980	MICB	Not yet druggable	Phosphatidylcholines	3	Increasing	1.05 (1.04; 1.07)	0	
Q9UNW1	MINP1	Not yet druggable	Phosphatidylcholines	1	Increasing	0.80 (0.73; 0.88)	0	
O14931	NCTR3	Not yet druggable	Phosphatidylcholines	1	Increasing	1.03 (1.02; 1.05)	0	
P29120	NEC1	Druggable	Phosphatidylcholines	3	Increasing	0.97 (0.96; 0.99)	0	
P15559	NQO1	Drugged	Sphingomyelins	1	Increasing	0.97 (0.96; 0.98)	4	
Q13018	PLA2R	Druggable	Amino acids	2	Increasing	1.01 (1.01; 1.02)	0	
Q9UIW2	PLXA1	Not yet druggable	Sphingomyelins	1	Increasing	0.90 (0.87; 0.92)	0	
O15031	PLXB2	Not yet druggable	Phosphatidylcholines	2	Increasing	1.03 (1.02; 1.04)	0	
P07949	RET	Drugged	Acylcarnitines, Phosphatidylcholines	5	Increasing	0.97 (0.96; 0.98)	14	Yes
Q96DX8	RTP4	Not yet druggable	Amino acids	1	Increasing	1.08 (1.06; 1.11)	0	
Q9UJH65	SWP70	Not yet druggable	Phosphatidylcholines	3	Increasing	0.96 (0.94; 0.97)	0	
P22105	TENX	Not yet druggable	Amino acids	1	Increasing	1.03 (1.02; 1.04)	0	
P49788	TIG1	Not yet druggable	Phosphatidylcholines, Sphingomyelins	3	Increasing	1.03 (1.02; 1.03)	0	
P25311	ZA2G	Not yet druggable	Phosphatidylcholines	2	Increasing	0.92 (0.90; 0.95)	0	

N.B. *Druggability* – whether the protein is targeted by a developmental (“druggable”) or approved (“drugged”) compound, *Metabolite class(es)* – metabolite class(es) of the metabolites with which the indicated protein is associated, *No. metabolites* – number of metabolites the protein is associated with, *Metabolite effect* – effect of protein on metabolites, defined as increasing if higher values of the protein increase the plasma metabolite values, decreasing if higher values of the protein decrease the metabolite values, and mixed if higher values of the protein increase values of some and decrease values of other metabolites, *Cardiac effect* – odds ratio (95% confidence interval) of the association between the

protein and atrial fibrillation (AF), *No. drugs* – number of drugs that target the indicated protein, *Cardiac drug effect* – whether at least one drug has a cardiac indication or side-effect as indicated by BNF or ChEMBL.

**Table 3.** Overview and characteristics of prioritised proteins and metabolites associated with DCM

<i>Uniprot ID</i>	<i>Protein</i>	<i>Druggability*</i>	<i>Metabolite class(es)*</i>	<i>No. metabolites*</i>	<i>Metabolite effect*</i>	<i>Cardiac effect*</i>	<i>No. drugs*</i>	<i>Cardiac drug effect*</i>
<i>P02654</i>	APOC1	Not yet druggable	Acylcarnitines	1	Increasing	1.49 (1.26; 1.77)	0	
<i>P02656</i>	APOC3	Druggable	Acylcarnitines	2	Increasing	2.15 (1.62; 2.85)	0	
<i>P43155</i>	CACP	Drugged	Acylcarnitines	1	Decreasing	3.15 (2.03; 4.90)	1	Yes
<i>Q9NZK5</i>	CECR1	Not yet druggable	Acylcarnitines	1	Decreasing	0.82 (0.76; 0.90)	0	
<i>P09543</i>	CN37	Not yet druggable	Acylcarnitines	2	Increasing	0.50 (0.43; 0.57)	0	
<i>P13929</i>	ENOB	Not yet druggable	Acylcarnitines	1	Decreasing	1.39 (1.28; 1.50)	0	
<i>P08637</i>	FCG3A	Druggable	Acylcarnitines	1	Decreasing	1.07 (1.05; 1.10)	1	
<i>Q4G148</i>	GXLT1	Not yet druggable	Acylcarnitines	1	Increasing	1.68 (1.34; 2.10)	0	
<i>Q8NFM7</i>	I17RD	Not yet druggable	Acylcarnitines	1	Increasing	0.76 (0.68; 0.86)	0	
<i>Q9BXS1</i>	IDI2	Not yet druggable	Acylcarnitines	1	Increasing	1.94 (1.57; 2.41)	0	
<i>Q9BW91</i>	NUDT9	Druggable	Acylcarnitines	1	Increasing	0.27 (0.15; 0.49)	0	
<i>Q13018</i>	PLA2R	Druggable	Acylcarnitines	1	Increasing	0.92 (0.91; 0.94)	0	
<i>Q9UGC7</i>	RF1ML	Not yet druggable	Acylcarnitines	1	Increasing	2.35 (1.93; 2.86)	0	
<i>Q96F10</i>	SAT2	Drugged	Acylcarnitines	3	Mixed	0.73 (0.64; 0.84)	1	Yes

N.B. *Druggability* – whether the protein is targeted by a developmental (“druggable”) or approved (“drugged”) compound, *Metabolite class(es)* – metabolite class(es) of the metabolites with which the indicated protein is associated, *No. metabolites* – number of metabolites the protein is associated with, *Metabolite effect* – effect of protein on metabolites, defined as increasing if higher values of the protein increase the plasma metabolite values, decreasing if higher values of the protein decrease the metabolite values, and mixed if higher values of the protein increase values of some and decrease values of other metabolites, *Cardiac effect* – odds ratio (95% confidence interval) of the association between the protein and atrial fibrillation (AF), *No. drugs* – number of drugs that target the indicated protein, *Cardiac drug effect* – whether at least one drug has a cardiac indication or side-effect as indicated by BNF or ChEMBL.

**Table 4.** Overview and characteristics of prioritised proteins and metabolites associated with NICM

<i>Uniprot ID</i>	<i>Protein</i>	<i>Druggability*</i>	<i>Metabolite class(es)*</i>	<i>No. metabolites*</i>	<i>Metabolite effect*</i>	<i>Cardiac effect*</i>	<i>No. drugs*</i>	<i>Cardiac drug effect*</i>
<i>P13929</i>	ENOB	Not yet druggable	Biogenic amines	1	Decreasing	1.24 (1.13; 1.35)	0	
<i>P14415</i>	AT1B2	Drugged	Biogenic amines	1	Decreasing	1.33 (1.19; 1.49)	6	Yes
<i>Q96NY8</i>	PVRL4	Drugged	Biogenic amines	1	Decreasing	0.32 (0.20; 0.51)	1	

N.B. *Druggability* – whether the protein is targeted by a developmental (“druggable”) or approved (“drugged”) compound, *Metabolite class(es)* – metabolite class(es) of the metabolites with which the indicated protein is associated, *No. metabolites* – number of metabolites the protein is associated with, *Metabolite effect* – effect of protein on metabolites, defined as increasing if higher values of the protein increase the plasma metabolite values, decreasing if higher values of the protein decrease the metabolite values, and mixed if higher values of the protein increase values of some and decrease values of other metabolites, *Cardiac effect* – odds ratio (95% confidence interval) of the association between the protein and atrial fibrillation (AF), *No. drugs* – number of drugs that target the indicated protein, *Cardiac drug effect* – whether at least one drug has a cardiac indication or side-effect as indicated by BNF or ChEMBL.

## Figures

### Figure 1. Study to identify plasma proteins and metabolites affecting cardiac disease

A) Flowchart of the analysis steps; B) A triangulation diagram, illustrating how a robust set of directionally concordant proteins was identified affecting plasma metabolite levels as well as cardiac disease. The red plus indicates a risk-increasing effect, while the blue minus indicates a risk-decreasing effect; C) Annotated network of prioritised metabolites, proteins, and outcomes for which the metabolites have at least 20% associated common proteins and belong to the metabolite class acylcarnitine. Prioritised directionally concordant proteins are represented by circles, metabolites by diamonds, outcomes by triangles. Circle colours represent protein druggability. Increasing effects are displayed by a red arrow, decreasing effects by a blue arrow. See **Supplementary Note** for more details.

Abbreviations: AF = atrial fibrillation, DCM = dilated cardiomyopathy, HF = heart failure, MR = mendelian randomisation, NICM = non-ischemic cardiomyopathy.

### Figure 2. Plasma metabolites associating with at least one cardiac outcome

N.B. For visualisation purposes, the p-values were truncated to a  $-\log(10)$  of 10. Multiplicity corrected significant associations are depicted by a star, non-significant associations by a dot. The top row indicates the number of druggable proteins reflecting information retrieved from BNF and ChEMBL. Genetic associations with the cardiac outcomes were obtained from Nielsen *et al.* (60,620 AF cases)<sup>33</sup>, Shah *et al.* (47,309 HF cases)<sup>34</sup>, Garnier *et al.* (2,719 DCM cases)<sup>35</sup>, and Aragam *et al.* (2,038 NICM cases)<sup>36</sup>. See the Methods section additional details, and Supplementary Table S2 for the underlying numerical data.

Abbreviations: a = acyl residue, aa = diacyl residue, ae = acyl-alkyl residue, AF = atrial fibrillation, DCM = dilated cardiomyopathy, HF = heart failure, LPC = lysophosphatidylcholine, NICM = non-ischemic cardiomyopathy, PC = phosphatidylcholine, SM = sphingomyelin.

**Figure 3. Cardiac mRNA expression of the subset of directionally concordant proteins affecting cardiac disease**

N.B. Proteins are referred to using their Uniprot label and proteins in bold font are overexpressed in cardiac tissue relative to non-cardiac tissue. Data were sourced from the human protein atlas; see Methods section.

**Figure 4. Forest plots of cardiac outcome effect of prioritised drugged or druggable proteins**




N.B. Metabolite class of the metabolites affected by the protein are indicated on the right y-axis. Genetic associations with the cardiac outcomes were obtained from Nielsen *et al.* (60,620 AF cases)<sup>33</sup>, Shah *et al.* (47,309 HF cases)<sup>34</sup>, Garnier *et al.* (2,719 DCM cases)<sup>35</sup>, and Aragam *et al.* (2,038 NICM cases)<sup>36</sup>. See the Methods section for a more detailed description and **Appendix Table S7-8** for the full numerical results.

Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HF = heart failure, NICM = non-ischemic cardiomyopathy, OR = odds ratio.

**Figure 5. Forest plot of prioritised proteins associating with more than one cardiac outcome**

N.B. . Metabolite class of the metabolites affected by the protein are indicated on the right y-axis. Genetic associations with the cardiac outcomes were obtained from Nielsen *et al.* (60,620 AF cases)<sup>33</sup>, Shah *et al.* (47,309 HF cases)<sup>34</sup>, Garnier *et al.* (2,719 DCM cases)<sup>35</sup>, and Aragam *et al.* (2,038 NICM cases)<sup>36</sup>. See the Methods section for a more detailed description and **Appendix Table S7** for the full numerical results.

Abbreviations: AF = atrial fibrillation, CI = confidence interval, DCM = dilated cardiomyopathy, HF = heart failure, NICM = non-ischemic cardiomyopathy, OR = odds ratio.











## Metabolite class:

■ Acylcarnitines 
 ■ Amino acids 
 ■ Biogenic amines 
 ■ Lysophosphatidylcholines 
 ■ Phosphatidylcholines 
 ■ Sphingomyelins

Drugged/druggable proteins






**AF****HF****DCM****NICM**

Metabolite class:

- Amino acids
- Lysophosphatidylcholines
- Biogenic amines
- Phosphatidylcholines
- Acylcarnitines
- Sphingomyelins



Metabolite class:

- |  |   |  |
|--|---|--|
| <span style="color: red;">■</span> Amino acids           | <span style="color: orange;">■</span> Acylcarnitines              | <span style="color: darkblue;">■</span> Phosphatidylcholines |
| <span style="color: lightblue;">■</span> Biogenic amines | <span style="color: darkgreen;">■</span> Lysophosphatidylcholines | <span style="color: mediumblue;">■</span> Sphingomyelins     |